Cancer Hospital Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
67 recruiting
Showing 1–20 of 114 trials
Recruiting
Phase 3
A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive
Non-small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company300 enrolled2 locationsNCT06930794
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled294 locationsNCT06926868
Recruiting
Phase 2
Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Non-small Cell Lung Cancer
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.60 enrolled1 locationNCT07329322
Recruiting
Phase 2
Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Non-small Cell Lung Cancer
Teligene US99 enrolled26 locationsNCT05168566
Recruiting
Phase 3
A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Gastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma
BeOne Medicines351 enrolled85 locationsNCT07043400
Recruiting
Phase 1
A Study of BG-C477 in Participants With Advanced Solid Tumors
Advanced Solid Tumors
BeOne Medicines310 enrolled32 locationsNCT06596473
Recruiting
Phase 1
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Breast CancerAdvanced Solid Tumor
BeOne Medicines86 enrolled23 locationsNCT07222267
Recruiting
Phase 2
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
MSI-H/dMMR Solid Tumors
BeiGene200 enrolled29 locationsNCT03736889
Recruiting
Phase 1
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Breast CancerGastric CancerOvarian Cancer+9 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting
Phase 3
A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer
Metastatic Colorectal Cancer
Taizhou Hanzhong biomedical co. LTD190 enrolled63 locationsNCT05652894
Recruiting
Phase 1
A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors
Advanced Solid Tumor
BeOne Medicines105 enrolled16 locationsNCT07226349
Recruiting
Phase 1
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
Advanced Solid Tumor
BeOne Medicines308 enrolled38 locationsNCT06233942
Recruiting
Phase 3
A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients
Non-small Cell Lung Cancer
Nuvation Bio Inc.194 enrolled29 locationsNCT06564324
Recruiting
Phase 2
A Phase IIa Study to Evaluate NBQ72S
Breast Cancer
Nantong Bencao Quadriga Medical Technology Co. Ltd.10 enrolled1 locationNCT06810804
Recruiting
Phase 1Phase 2
A Study Explore WJB001 Capsules in Patients With Advanced Solid Tumors
Advanced Solid Tumors
Wigen Biomedicine Technology (Shanghai) Co., Ltd.210 enrolled11 locationsNCT05773820
Recruiting
Early Phase 1
A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma
Suzhou Immunofoco Biotechnology Co., Ltd30 enrolled4 locationsNCT07376642
Recruiting
Phase 1
A Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HRS-3802 Monotherapy in Patients With Malignant Solid Tumors
Advanced Solid Tumors
Shandong Suncadia Medicine Co., Ltd.100 enrolled6 locationsNCT06770569
Recruiting
Phase 1Phase 2
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors
Advanced Solid Tumor
Wigen Biomedicine Technology (Shanghai) Co., Ltd.86 enrolled10 locationsNCT06953323
Recruiting
Phase 2
Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.134 enrolled32 locationsNCT06897579
Recruiting
Phase 1
An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Advanced Solid Tumor
BeOne Medicines244 enrolled62 locationsNCT06589596